Should You Refer to a Vascular Neurologist (Stroke Specialist)?
Yes, referral to a vascular neurologist with stroke expertise is strongly recommended for patients with suspected or confirmed cerebral amyloid angiopathy (CAA), given the high mortality, morbidity, and recurrence rates associated with CAA-related intracerebral hemorrhage, along with the complex management decisions required. 1
Why Stroke Neurology Expertise is Critical
CAA is explicitly recognized as a cerebrovascular disease requiring specialized stroke neurology care. The 2025 International CAA Association and World Stroke Organization guidelines emphasize that CAA represents "a stroke subtype with among the highest mortality, morbidity, and recurrence rate across the stroke spectrum" 1. This is not a general neurology condition—it fundamentally involves stroke pathophysiology and requires expertise in:
- Hemorrhagic stroke management: CAA is a major cause of spontaneous lobar intracerebral hemorrhage with devastating outcomes 1
- Stroke risk stratification: Patients with certain CAA presentations (particularly transient focal neurological episodes with cortical superficial siderosis) face an estimated 19% annual hemorrhage risk 1
- Complex antithrombotic decisions: Balancing thrombotic versus hemorrhagic risk requires specialized stroke expertise 1
Specific Expertise a Stroke Neurologist Provides
Diagnostic Precision
A vascular neurologist can:
- Apply the Boston Criteria v2.0 for CAA diagnosis using specialized MRI sequences (FLAIR, T2*-weighted/SWI, diffusion-weighted imaging, contrast-enhanced sequences) 1
- Distinguish CAA-related transient focal neurological episodes from true TIAs—a critical distinction since misdiagnosis leads to inappropriate antithrombotic therapy that increases hemorrhage risk 1, 2
- Recognize CAA-related inflammation requiring immunosuppression versus standard CAA management 1
High-Stakes Management Decisions
The stroke neurologist must navigate:
Blood pressure management: Aggressive control (systolic <140 mmHg acutely, <130 mmHg long-term) can reduce ICH risk by 77% in probable CAA 1, 3
Antithrombotic therapy: This requires specialized risk-benefit analysis since:
- 70% of patients with hemorrhage after thrombolytic therapy have CAA 3
- Anticoagulation and antiplatelet agents substantially increase hemorrhage risk in CAA patients 3, 4
- Yet some patients have compelling thrombotic indications requiring individualized approaches 4, 5
Alzheimer's disease immunotherapy: Patients with CAA face high risk for amyloid-related imaging abnormalities (ARIA) with anti-amyloid monoclonal antibodies; those with ICH or >4 cerebral microbleeds should be excluded from treatment 1
Common Pitfall to Avoid
Do not treat suspected CAA-related transient focal neurological episodes as TIAs with antithrombotic therapy. These episodes frequently represent bleeding (superficial cortical siderosis or convexity subarachnoid hemorrhage) rather than ischemia 1, 2. Starting antiplatelet or anticoagulant therapy in this setting dramatically increases the risk of catastrophic intracerebral hemorrhage. A stroke neurologist recognizes the spreading progression of symptoms over minutes and high recurrence rate that distinguish these from true TIAs 1.
When Referral is Most Urgent
Immediate stroke neurology consultation is indicated for:
- Any lobar intracerebral hemorrhage in patients >55 years
- Transient focal neurological episodes with MRI evidence of cortical superficial siderosis or convexity subarachnoid hemorrhage
- Subacute encephalopathy with asymmetric white matter changes (possible CAA-related inflammation requiring urgent immunosuppression) 1
- Patients on or being considered for anticoagulation who have lobar microbleeds on MRI
The complexity of CAA management—spanning hemorrhagic stroke prevention, antithrombotic decision-making, blood pressure optimization, and recognition of inflammatory variants—makes vascular neurology expertise essential rather than optional for optimizing patient outcomes.